Literature DB >> 19352698

Histopathology report of cutaneous melanoma and sentinel lymph node in Europe: a web-based survey by the Dermatopathology Working Group of the European Society of Pathology.

Anna Batistatou1, Martin G Cook, Daniela Massi.   

Abstract

In order to survey the diagnostic reporting of melanomas by European pathologists and assess their current practice and opinions on the information required in the final report, a web-based questionnaire was diffused through the members of the Dermatopathology Working Group of the European Society of Pathology. Forty replies from different pathology laboratories were collected (49%). Main prognostic parameters related to the primary tumor, including Breslow thickness, presence of ulceration, and Clark's level, as well as additional features, are reported by a large majority of laboratories. Presence of regression is reported by 90% of respondents but with different recording items. For sentinel lymph node (SLN) biopsy for melanoma, the conventional panel of antibodies includes S-100, Melan A, and HMB45. Dissection of the SLN is performed by "bivalve" or "bread loaf" approach. The number of sections cut and stained varies. Forty-four percent of respondents report depths of metastases from the capsule, while the majority report maximum dimension of the largest deposit. Results indicate that pathology reports for primary cutaneous melanoma and SLN vary between laboratories across Europe. Although the most important prognostic features are universally reported, key features which impact on prognosis and treatment are often omitted and others still require standardization.

Entities:  

Mesh:

Year:  2009        PMID: 19352698     DOI: 10.1007/s00428-009-0763-5

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  36 in total

Review 1.  Cutaneous melanoma.

Authors:  John F Thompson; Richard A Scolyer; Richard F Kefford
Journal:  Lancet       Date:  2005 Feb 19-25       Impact factor: 79.321

Review 2.  Morphological and immunophenotypic variations in malignant melanoma.

Authors:  S S Banerjee; M Harris
Journal:  Histopathology       Date:  2000-05       Impact factor: 5.087

3.  Model predicting survival in stage I melanoma based on tumor progression.

Authors:  W H Clark; D E Elder; D Guerry; L E Braitman; B J Trock; D Schultz; M Synnestvedt; A C Halpern
Journal:  J Natl Cancer Inst       Date:  1989-12-20       Impact factor: 13.506

4.  The evaluation of diagnostic and prognostic criteria and the terminology of thin cutaneous malignant melanoma by the CRC Melanoma Pathology Panel.

Authors:  M G Cook; T J Clarke; S Humphreys; A Fletcher; K M McLaren; N P Smith; A Stevens; J M Theaker; J Melia
Journal:  Histopathology       Date:  1996-06       Impact factor: 5.087

5.  The development of optimal pathological assessment of sentinel lymph nodes for melanoma.

Authors:  Martin G Cook; Margaret A Green; Brian Anderson; Alexander M M Eggermont; Dirk J Ruiter; Alain Spatz; Mark W Kissin; Barry W E M Powell
Journal:  J Pathol       Date:  2003-07       Impact factor: 7.996

6.  The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up.

Authors:  Anne Brecht Francken; Helen M Shaw; John F Thompson; Seng-jaw Soong; Neil A Accortt; Manuela F Azzola; Richard A Scolyer; Gerald W Milton; William H McCarthy; Marjorie H Colman; Vincent J McGovern
Journal:  Ann Surg Oncol       Date:  2004-03-15       Impact factor: 5.344

Review 7.  Pathologic examination of sentinel lymph nodes from melanoma patients.

Authors:  Richard A Scolyer; Rajmohan Murali; Stanley W McCarthy; John F Thompson
Journal:  Semin Diagn Pathol       Date:  2008-05       Impact factor: 3.464

8.  Is superficial spreading melanoma still the most common form of malignant melanoma?

Authors:  Seth B Forman; Tammie C Ferringer; Steven J Peckham; Scott R Dalton; Geoff T Sasaki; Lester F Libow; Dirk M Elston
Journal:  J Am Acad Dermatol       Date:  2008-06       Impact factor: 11.527

9.  Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging.

Authors:  Phyllis A Gimotty; DuPont Guerry; Michael E Ming; Rosalie Elenitsas; Xiaowei Xu; Brian Czerniecki; Francis Spitz; Lynn Schuchter; David Elder
Journal:  J Clin Oncol       Date:  2004-08-09       Impact factor: 44.544

10.  The regressing thin malignant melanoma: a distinctive lesion with metastatic potential.

Authors:  M A Gromet; W L Epstein; M S Blois
Journal:  Cancer       Date:  1978-11       Impact factor: 6.860

View more
  3 in total

1.  Melanoma histopathology report: proposal for a standardized terminology.

Authors:  Anna Batistatou; Ozay Gököz; Martin G Cook; Daniela Massi
Journal:  Virchows Arch       Date:  2010-12-31       Impact factor: 4.064

2.  The anticancer activity of visnagin, isolated from Ammi visnaga L., against the human malignant melanoma cell lines, HT 144.

Authors:  Fatma Aydoğmuş-Öztürk; Humera Jahan; Neslihan Beyazit; Keriman Günaydın; Muhammad Iqbal Choudhary
Journal:  Mol Biol Rep       Date:  2019-01-29       Impact factor: 2.316

3.  Parkinson's disease-related protein, alpha-synuclein, in malignant melanoma.

Authors:  Yasuhiro Matsuo; Tetsu Kamitani
Journal:  PLoS One       Date:  2010-05-05       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.